BCRX NASDAQ
BioCryst Pharmaceuticals, Inc.
1W: +2.0%
1M: -4.4%
3M: -15.0%
YTD: +8.0%
1Y: +12.5%
3Y: +37.8%
5Y: -46.1%
$8.10
+0.22 (+2.79%)
Weekly Expected Move ±5.3%
$7
$7
$8
$8
$8
Credit Risk of going bust: lower than 54% of companies Debt: 16.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.15 (down 98%), BioCryst Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $409.9M against a stock market value of $2.07B.
Distance to default 5.48 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $197.7M (short-term plus half of long-term), stock volatility 47.5%; Altman Z'' -13.51. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.15 (down 98%), BioCryst Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $409.9M against a stock market value of $2.07B.
Distance to default 5.48 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $197.7M (short-term plus half of long-term), stock volatility 47.5%; Altman Z'' -13.51. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Balance Sheet Trends
Total Assets
$514M
+4.8% ▲
5Y CAGR: +9.0%
Total Liabilities
$633M
-34.5% ▼
5Y CAGR: +12.3%
Shareholders Equity
-$119M
+75.0% ▲
Cash & Investments
$275M
-14.4% ▼
5Y CAGR: -1.8%
Total Debt
$477M
-43.3% ▼
5Y CAGR: +11.3%
Net Debt
$388M
-47.4% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $504M | $305M | $111M | $105M | $90M |
| Short-Term Investments | $3M | $120M | $278M | $216M | $185M |
| Cash & ST Investments | $508M | $424M | $389M | $321M | $275M |
| Net Receivables | $29M | $51M | $57M | $79M | $107M |
| Inventory | $16M | $28M | $29M | $8M | $5M |
| Other Current Assets | $3M | $14M | $21M | $14M | $17M |
| Total Current Assets | $566M | $516M | $496M | $422M | $404M |
| Property, Plant & Equip. | $15M | $9M | $21M | $20M | $19M |
| Goodwill & Intangibles | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $7M | $18M | $0 | $22M | $61M |
| Other Non-Current Assets | $0 | $7M | $80K | $27M | $30M |
| Total Non-Current Assets | $22M | $34M | $21M | $68M | $110M |
| Total Assets | $588M | $550M | $517M | $490M | $514M |
| — Liabilities — | |||||
| Accounts Payable | $28M | $14M | $21M | $12M | $16M |
| Short-Term Debt | $0 | $0 | $0 | $35M | $40M |
| Deferred Revenue | $1M | $1M | $0 | $0 | $0 |
| Other Current Liabilities | $52M | $36M | $87M | $65M | $140M |
| Total Current Liabilities | $104M | $106M | $150M | $160M | $196M |
| Long-Term Debt | $585M | $733M | $811M | $796M | $427M |
| Other Non-Current Liab. | $0 | $0 | $0 | $0 | $0 |
| Total Non-Current Liabilities | $591M | $739M | $822M | $806M | $437M |
| Total Liabilities | $695M | $845M | $972M | $966M | $633M |
| — Equity — | |||||
| Common Stock | $2M | $2M | $2M | $2M | $2M |
| Retained Earnings | -$1.2B | -$1.5B | -$1.7B | -$1.8B | -$1.5B |
| Accumulated OCI | $177K | $26K | $1M | $921K | $38K |
| Total Stockholders Equity | -$107M | -$295M | -$456M | -$476M | -$119M |
| Total Liabilities & Equity | $588M | $550M | $517M | $490M | $514M |
| — Key Metrics — | |||||
| Total Debt | $593M | $741M | $825M | $841M | $477M |
| Net Debt | $89M | $437M | $715M | $736M | $388M |
| Total Investments | $10M | $138M | $278M | $238M | $246M |